Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
Study Details
Study Description
Brief Summary
This phase I/II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of patients with cancer for which no treatment is currently available. Psilocybin is a substance being studied for the treatment of anxiety or depression in patients with advanced cancer. It is taken from the mushroom psilocybe mexicana. Psilocybin acts on the brain to cause hallucinations (sights, sounds, smells, tastes, or touches that a person believes to be real but are not real). Giving psilocybin in combination with therapy may decrease anxiety in patients with metastatic cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
OUTLINE:
Patients receive psilocybin orally (PO) and participate in group and individual therapy sessions on trial.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment (psilocybin, therapy) Patients receive psilocybin PO and participate in group and individual therapy sessions on trial. |
Other: Counseling
Participate in therapy visits
Other Names:
Drug: Psilocybin
Given PO
Other Names:
Other: Questionnaire Administration
Ancillary studies
|
Outcome Measures
Primary Outcome Measures
- Number of instances of potentially unattended psilocybin-related distress during psilocybin sessions. [At psilocybin administration session on day 0]
Defined as the occurrence of participant distress among study participants in the small group during the psilocybin administration session on Day 0 that requires 1:1 facilitator attention that cannot be met by the 4-person facilitation team. The size of small groups of different sizes will vary over the course of the study. Descriptive statistics will be used to analyze and will be tabulated after each group intervention (which will happen approximately every month). Backup facilitators will be available when this occurs.
Secondary Outcome Measures
- Change in measured anxiety and depression: Hospital Anxiety and Depression Scale (HADS) [From 14 days before the psilocybin session to 28 days (4 weeks) after the psilocybin session]
The Hospital Anxiety and Depression Scale (HADS) is a self-administered measure of depression and anxiety. The HADS is not a diagnostic tool, but can screen for anxiety and depression. The HADS has 14 items in total and asks about mood in the past week. Seven items assess depression and seven items assess anxiety. The HADS can be administered repeatedly without impacting on validity. Each item is rated on a 4-point scale and provide a score 0-21. A higher score indicates higher distress.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
A diagnosis of metastatic solid tumor, or incurable hematologic malignancy that has been accepted by a physician in a medical record
-
Measurable disease is not required
-
Previous treatment with chemotherapy: There are no minimum or maximum prior lines of chemotherapy
-
18-80 years of age
-
Required performance status, including the appropriate scale. Eastern Cooperative Oncology Group (ECOG) 0-2
-
Hematocrit > 20
-
Platelets (Plt) > 20K
-
Liver function tests 1.5 x normal
-
Creatinine 1.5 x normal
-
Subjects of childbearing potential must be willing to use an effective contraceptive method from study enrollment until at least 1 month after receiving the investigational agent(s)
-
Must be at least 4 weeks after surgery or radiotherapy at study entry, but can be receiving oral or iv chemotherapy if those schedules can be adjusted around the medication session date
-
Motivated to participate in a group study and able in the research team's judgment to participate in the small group effectively
-
On pre-enrollment screening tests, they will have clinically significant anxiety or depressive symptoms as defined by a score of 11 or greater on the Hospital Anxiety and Depression Scale (HADS)-Total
-
English speaking- able to understand the process of consent and the risk and benefits associated with the study, and able to give written informed consent. This is a pilot study, and if future larger studies are designed, consideration will be given for non-English-speaking subjects
-
Must be willing to sign a medical release for the investigators to communicate directly with their treating clinicians (mental health professional or oncologist) and doctors to confirm a medication and/or medical history
-
Must provide at least one adult who is in contact with the participant at least once a day when the participant is at home who is able to verbally monitor participant-reported changes in the behavior and able to notify research staff of behavior changes that may require research staff assessment
-
Has been off selective serotonin inhibitors for five half-lives of the drug plus 2 weeks
-
Must avoid taking any psychiatric medications or starting a new psychiatric medication during the study. Should participant's doctor recommend starting a new psychiatric medication, participant will be required to notify the study team and the subject would withdraw from the study. (Use of prn benzodiazepines is allowed but high dose chronic benzodiazepine use must be reviewed by the principal investigator [PI]. Use of as needed [prn] gabapentoids is allowed by high dose chronic gabapentoid use must be reviewed by the PI)
-
Must provide a contact (relative, spouse, close friend, or other caregiver; can be the same person) who is willing and able to be reached by the research team in the event that the participant becomes suicidal
-
If the potential participant is of childbearing potential, they must have a negative pregnancy test at baseline and prior to the medication dosing session, and must agree to use adequate birth control
-
Are willing to commit to preparation sessions, medication dosing sessions, integration sessions, to complete evaluation instruments and commit to be contacted for all necessary telephone contacts
Exclusion Criteria:
-
Brain metastases that have not been treated
-
Uncontrolled or concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Pregnancy, breastfeeding, or expecting to conceive or father children for the duration of the trial through 30 days after receipt of investigational agent(s)
-
Personal or immediate family history of schizophrenia, bipolar affective disorder, delusion disorder, paranoid disorder, or schizoaffective disorder
-
Suicidal ideation with a Columbia-Suicidality Severity Rating Scale (C-SSRS) >= 3
-
Current substance abuse disorder (although prospective subjects will not be excluded for reasonable alcohol use that does not meet criteria for alcohol use disorder or marijuana use that does not meet criteria for substance use disorder)
-
Neuroleptic (including olanzapine, prochlorperazine, promethazine), and selective serotonin reuptake inhibitor (SSRI) medications that cannot be tapered and discontinued in conjunction with the participant's prescribing physician (although ondansetron can be used for nausea)
-
Unstable neurological or medical condition; history of seizure, chronic/severe headaches
-
Any use of psychedelic drugs in high doses (psilocybin > 2 grams of dried mushrooms, LSD > 200 micrograms) within the prior 12 months (microdosing will not require exclusion but participants would have to agree to discontinue microdosing 1 month before study entry)
-
Use of tramadol, due to the potential for serotonin syndrome with concomitant use of psilocybin
-
Individuals who are on MOAI (monoamine oxidase inhibitors) or who have a known sensitivity to the drug or its metabolites. Psilocybin is contraindicated in medications that are known UGT (UDP-glucuronosyltransferase) enzyme modulators. The concurrent use of SSRI/serotonin-norepinephrine reuptake inhibitor (SNRI) meds is assumed to be contraindicated due to the potential to increase the risk of serotonin syndrome and/or to attenuate the binding of psilocin to the HT2A receptor
-
A marked baseline prolongation of QT/corrected QT (QTc) interval (e.g., demonstration on > 1 electrocardiogram (ECG) of a QTc interval > 450 milliseconds (ms)
-
A history of additional risk factors for Torsade de Points (including but not limited to: heart failure, hypokalemia, family history of long QT syndrome)
-
The use of concomitant medications that prolong the QT/QTc interval
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | United States | 98109 |
Sponsors and Collaborators
- University of Washington
- Steven and Alexandra Cohen Foundation
Investigators
- Principal Investigator: Anthony Back, Fred Hutch/University of Washington Cancer Consortium
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RG1123316
- NCI-2023-02948
- RG1123316